Pegcetacoplan
Phase 2Recruiting 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria
Trial Timeline
Feb 4, 2021 → Dec 1, 2028
NCT ID
NCT04901936About Pegcetacoplan
Pegcetacoplan is a phase 2 stage product being developed by Apellis Pharmaceuticals for Paroxysmal Nocturnal Hemoglobinuria (PNH). The current trial status is recruiting. This product is registered under clinical trial identifier NCT04901936. Target conditions include Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04729062 | Pre-clinical | Completed |
| NCT07020832 | Phase 3 | Recruiting |
| NCT06161584 | Pre-clinical | Active |
| NCT05809531 | Phase 3 | Active |
| NCT05067127 | Phase 3 | Completed |
| NCT04572854 | Phase 2 | Active |
| NCT04901936 | Phase 2 | Recruiting |
| NCT03531255 | Phase 3 | Active |
| NCT03593200 | Phase 2 | Completed |
| NCT03465709 | Phase 1/2 | Terminated |
| NCT02588833 | Phase 1 | Completed |
| NCT02503332 | Phase 2 | Completed |
| NCT02264639 | Phase 1 | Completed |
| NCT02461771 | Phase 1 | Completed |
Competing Products
20 competing products in Paroxysmal Nocturnal Hemoglobinuria (PNH)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Crovalimab + Placebo | Chugai Pharmaceutical | Phase 1/2 | 41 |
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Ravulizumab | AstraZeneca | Pre-clinical | 23 |
| Eculizumab | AstraZeneca | Phase 3 | 77 |
| Danicopan | AstraZeneca | Phase 3 | 77 |
| LNP023 | Novartis | Pre-clinical | 23 |
| Iptacopan (LNP023) | Novartis | Phase 3 | 77 |
| iptacopan | Novartis | Phase 2 | 52 |
| LNP023 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Pre-clinical | 23 |
| Iptacopan | Novartis | Phase 3 | 77 |
| LNP023 + Eculizumab + Ravulizumab | Novartis | Phase 3 | 77 |
| LNP023 | Novartis | Phase 3 | 77 |
| LFG316 + LNP023 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Phase 3 | 77 |
| Crovalimab | Roche | Phase 3 | 77 |
| ABP 959 + Eculizumab | Amgen | Phase 3 | 76 |
| Pegcetacoplan | Swedish Orphan Biovitrum | Pre-clinical | 22 |
| BMS-919373 + Placebo (Matching with BMS-919373) | Bristol Myers Squibb | Phase 2 | 51 |